Abstract 2566
Background
Data on functional imaging parameters such as blood volume (BV) in metastatic renal cell carcinoma (mRCC) is limited. We assessed the association of baseline BV with survival outcome adjusted for baseline clinical factor in patients with mRCC.
Methods
BV was quantified using dynamic contrast-enhanced computed tomography in patients from two prospective studies; Angiogenesis Inhibitor Study (AIS) with pazopanib, sunitinib and temsirolimus and the Danish Renal Cancer Group Study-1 (Darenca-1) with interleukin-2, interferon alpha with or without bevacizumab. Data were analyzed using an Advanced Perfusion and Permeability Application softwareprogram, Phillips. BV was evaluated as a binary (above/below median) and as a continuous variable adjusted for treatment, gender, and individual IMDC factors. Association was evaluated using chi squared test for clinical factors, Cox regression for overall survival (OS) and progression-free survival (PFS), and logistic regression for objective response rate (ORR).
Results
Among 122 included patients, 105 patients had technically feasible scans and were included in the final analysis (AIS, N = 29 and Darenca-1, N = 76). Median BV was 32.87 mL * 100 g-1 (range 9.52 to 92.87). BV above median was associated with IMDC favorable risk group (p = 0.004), metastasis free interval > 1 year (p = 0.007) and male gender (p = 0.032). BV below median was associated with anemia (p = 0.040) and neutrophilia (p = 0.007). Patients with high vs. low baseline BV had longer PFS (12.5 vs. 5.6 months, p = 0.015) and longer OS (42.2 vs. 22.4 months, p = 0.001), respectively. In multivariate analysis, high baseline BV remained an independent favorable prognostic factor (OS: HR 0.49, 95% CI 0,30-0,78, p = 0.003, PFS: HR 0.64; 95% CI 0,42-0,97, p = 0.040). BV analyzed as a continuous variable was also associated with OS in multivariate analysis (HR 0.98, 95% CI 0,96-1,00, p = 0,017). No association was found between BV and ORR (OR 1.56; 95% CI 0,67-3,63, p = 0.3).
Conclusions
High baseline BV, obtained using functional imaging, is a new independent favorable prognostic factor associated with longer PFS and OS in patients with mRCC. Further research in functional imaging is encouraged.
Clinical trial identification
NCT01274273 (Darenca-1 Study).
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Phillips Healthcare provided the software used for DCE-CT analysis Roche and Novartis supported the clinical part of the study financially - but were however not invovled in the imaging analysis.
Disclosure
A. Drljevic-Nielsen: Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: BMS. F. Donskov: Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
5678 - Nanomaterials Augmented LDI-TOF-MS for Hepatocellular Carcinoma Diagnosis and Classification
Presenter: Jian Zhou
Session: Poster Display session 3
Resources:
Abstract
2436 - Development and Validation of an RNA-Seq Assay for Gene Fusions Detection in Formalin-Fixed Paraffin-Embedded Samples
Presenter: Hua Dong
Session: Poster Display session 3
Resources:
Abstract
5271 - A Pilot Study to Implement an Artificial Intelligence (AI) System for Gastrointestinal Cancer Clinical Trial Matching
Presenter: Zhaohui Jin
Session: Poster Display session 3
Resources:
Abstract
4787 - A Blinded Comparison of Patient Treatments to Therapeutic Options Presented by an Artificial Intelligence-based Clinical Decision-support system
Presenter: Suthida Suwanvecho
Session: Poster Display session 3
Resources:
Abstract
5744 - OncOS: scalable and accurate next-generation sequencing analytics for precision oncology and personalized patient care
Presenter: Joe Thompson
Session: Poster Display session 3
Resources:
Abstract
3752 - The association between wearable device physical activity metrics and performance status in oncology: a systematic review
Presenter: Milan Kos
Session: Poster Display session 3
Resources:
Abstract
5820 - SomaticNET: neural network evaluation of somatic mutations in cancer
Presenter: Geoffroy Dubourg-Felonneau
Session: Poster Display session 3
Resources:
Abstract
4771 - Is there a role for Next-generation sequencing (NGS) profiling on metastatic non-colorectal gastrointestinal carcinomas (MNCGIC) in developing countries? A single center experience.
Presenter: Mauricio Ribeiro
Session: Poster Display session 3
Resources:
Abstract
1209 - Metastatic Cancer Whole-Exome Sequencing in daily practice
Presenter: Manon Réda
Session: Poster Display session 3
Resources:
Abstract
5702 - Genomic-Guided Individualized Precision Therapy in Refractory Metastatic Solid Tumor Patients with Extensively Poor Performance Status: A Chinese single institutional prospective observational real-world study
Presenter: Haitao Wang
Session: Poster Display session 3
Resources:
Abstract